These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19643598)

  • 21. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    Hurwitz H; Fehrenbacher L; Novotny W; Cartwright T; Hainsworth J; Heim W; Berlin J; Baron A; Griffing S; Holmgren E; Ferrara N; Fyfe G; Rogers B; Ross R; Kabbinavar F
    N Engl J Med; 2004 Jun; 350(23):2335-42. PubMed ID: 15175435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of bevacizumab as first-line therapy for colon cancer.
    Marshall J
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S43-7. PubMed ID: 16399431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
    Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
    Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
    Longo F; Mansueto G
    Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
    [No Abstract]   [Full Text] [Related]  

  • 26. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
    Hurwitz HI; Yi J; Ince W; Novotny WF; Rosen O
    Oncologist; 2009 Jan; 14(1):22-8. PubMed ID: 19144677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of bevacizumab for advanced colorectal cancer].
    Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
    J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.
    Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Maspero F; Sauta MG; Beretta GD; Barni S
    Clin Colorectal Cancer; 2013 Sep; 12(3):145-51. PubMed ID: 23763824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The treatment of colorectal carcinoma: standard chemotherapy and beyond.
    Eng C; Abbruzzese JL
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):592-8. PubMed ID: 16163242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of colorectal cancer with and without bevacizumab: a phase III study.
    Stathopoulos GP; Batziou C; Trafalis D; Koutantos J; Batzios S; Stathopoulos J; Legakis J; Armakolas A
    Oncology; 2010; 78(5-6):376-81. PubMed ID: 20798560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].
    Cui F; Chen JZ; Wan C; Chen B; Luo RC; Zheng H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jul; 12(4):374-7. PubMed ID: 19598023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Rivera F; Valladares M; Gea S; López-Martínez N
    J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab for advanced colorectal cancer.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Dec; (63):1-4. PubMed ID: 15612152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
    Avallone A; Piccirillo MC; Aloj L; Nasti G; Delrio P; Izzo F; Di Gennaro E; Tatangelo F; Granata V; Cavalcanti E; Maiolino P; Bianco F; Aprea P; De Bellis M; Pecori B; Rosati G; Carlomagno C; Bertolini A; Gallo C; Romano C; Leone A; Caracò C; de Lutio di Castelguidone E; Daniele G; Catalano O; Botti G; Petrillo A; Romano GM; Iaffaioli VR; Lastoria S; Perrone F; Budillon A
    BMC Cancer; 2016 Feb; 16():69. PubMed ID: 26857924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
    Prescrire Int; 2014 Sep; 23(152):205. PubMed ID: 25325116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
    Tsutsumi S; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Asao T; Kuwano H
    Hepatogastroenterology; 2014 May; 61(131):633-7. PubMed ID: 26176048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
    Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].
    Mansueto G; Longo F
    Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.